Latest News about UCBJF
Recent news which mentions UCBJF
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
September 24, 2024
From Benzinga
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
September 10, 2024
From Benzinga
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
August 29, 2024
From Benzinga
Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies
August 26, 2024
From Benzinga
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
January 02, 2024
From Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
September 28, 2023
From Benzinga
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
August 31, 2023
From Benzinga
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
June 27, 2023
From Benzinga
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
February 14, 2023
From Benzinga
UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
March 28, 2022
From Benzinga
From Benzinga
From Benzinga
Why Zogenix Flew Higher Before Leveling Off This Week
January 21, 2022
From Motley Fool
From Benzinga
UCB Gets EU Approval For Bimekizumab In Psoriasis
August 25, 2021
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.